Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. - Wikidata - wikimedia - TriplyDB

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

http://www.wikidata.org/entity/Q37947095

about

Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health Treatment Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists Brexpiprazole: so far so good Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications Genetics of Common Antipsychotic-Induced Adverse Effects Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications Physical health policies and metabolic screening in mental health care systems of sub-Saharan African countries: a systematic review Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study Methods for using clinical laboratory test results as baseline confounders in multi-site observational database studies when missing data are expected.Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk.Long-term risperidone treatment induces visceral adiposity associated with hepatic steatosis in mice: a magnetic resonance approach The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population.Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice.Classics in Chemical Neuroscience: Aripiprazole.Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables.Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescents Almost all antipsychotics result in weight gain: a meta-analysis.The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial.Improving physical health and reducing substance use in psychosis--randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender.Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study.Cardiovascular risk factors and 30-year cardiovascular risk in homeless adults with mental illness Metformin and berberine prevent olanzapine-induced weight gain in rats Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study.Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics

P2860

Q24606868-B3B375BD-C022-45D4-9A3E-E9146BC628BC Q26741515-5984BE18-9234-4E67-AB5D-BDF261A74909 Q26747123-D6DB8B87-4D83-4C00-BBD5-71C058860D04 Q26766401-4D0E6874-04C5-41CD-AE70-30C54D59DAE0 Q26864342-7DFBBE05-8B15-4E4E-943C-3A85390FC51D Q27027832-C996A87E-6C17-4B8C-9501-BF8BA065BC92 Q28066646-AFA76452-52C4-46AB-95E8-4AC70AFE51DC Q28072893-CC46BCD0-64C8-460B-9C5C-B65A1DB34ACD Q28295134-4BEBB16E-A63D-4EFE-BD3C-4BC390A6F8EF Q29994580-260AC2F4-DC1F-4C5D-8C1B-ACDA2025C5B9 Q30627430-1ABD7D9E-3A1C-4DB7-82D8-935920B4B66F Q31090636-125B450E-361A-4227-9C01-FA3035737EA9 Q31147850-822BEFCE-62FE-4AAE-B9F2-DF32840419D6 Q33607534-6AA7CD7D-B651-4BE4-BE1C-D101BC585289 Q33619940-A1281116-84D8-4E85-B39A-E2FE4C968087 Q33622056-F6AA0499-2298-4B86-B2A9-B61388725492 Q33670588-2D42444D-7F52-4681-B658-A88D7DDF7E85 Q33695789-361A7C27-2165-4ACD-91D9-144B3C1AF2CB Q33713759-07A97048-53FC-46CC-9709-D0DBF15B7970 Q33802927-5E7EC2A6-6339-4130-B67F-B04652A8014D Q33850466-F79EB5DB-117A-404D-8729-4FA2E7F180BE Q33866125-36AF4BBD-C500-40AE-9A67-DAD492B0F9A4 Q33878816-BD08CEC1-C10A-47A3-8519-1C3593515F4F Q34086096-4E2F4078-4BEC-49F3-9682-DDDFFCD8CE04 Q34315836-E6D0180F-9173-44E3-8316-17C9A9F3B34F Q34376884-6F79D26F-93B8-4AF3-858E-60CEB17BA14D Q34379379-BDAA673D-58E8-41BD-9BA0-2E7700DDC554 Q34386877-3E4699B6-1BB0-4C1B-AC5A-BE1C60A06100 Q34464293-28FC464C-E7D8-44F4-9C86-8BE0DBF19C2D Q34641561-8149F575-5544-43AB-88B9-A4E5303F0253 Q34659629-51928A84-E7B5-4AE1-8AC2-A58D2B2FFB30 Q34661499-DBFA7328-57A2-4EB8-BC12-35CCBA64EA94 Q34807210-567D85C6-B15D-410A-B72D-202A775CBACB Q35019136-544FD8EA-7EE3-4B17-A47A-9AD093B2BF07 Q35075344-BE281AD8-0928-48F5-8EF0-72E16E135497 Q35087495-05BFA054-47C2-4094-916A-6A5D05DA1863 Q35118808-58FC65A8-8449-43B9-A14F-0472AF930B77 Q35131343-85843A5A-A092-41A6-B89E-61569B5840F4 Q35135720-CFBCFA36-C0C6-4FA9-AA99-7B0757A46B05 Q35330607-265AB5E4-C7DD-4EC5-A4B0-85A249E17F6D

P2860

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

http://www.wikidata.org/entity/Q37947095

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

@en

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

@nl

type

label

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

@en

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

@nl

prefLabel

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

@en

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

@nl

P1433

Q37947095-0736B046-5816-4E9A-ADD5-294CFBE204A0

P1476

Q37947095-BB257730-366A-4EC0-8511-B12716A18492

P2093

Q37947095-075418AF-D74C-4819-88D5-068CD7548EB0

Q37947095-BA15ED8B-9FB3-48F0-8562-659C4D116408

Q37947095-CBA8860E-34A6-4022-99FF-A9533B9F9FED

Q37947095-E7973A77-1E0D-4026-8C01-9D7155475D3C

Q37947095-FEC68C68-57E4-4C18-A391-2B16381FE2BC

P2860

Q37947095-0207FFF7-0C14-492A-9800-114E4CE79F91

Q37947095-0511CCAE-44E4-4240-B1AE-EB594EAA0CAA

Q37947095-0568E644-B4A0-4D96-8196-A64F53C469BB

Q37947095-07D931D5-CF32-4632-987F-47E5CD2172ED

Q37947095-0941BED5-3EC2-4541-92F1-B967D5E69616

Q37947095-0A6267DC-3C3C-49B1-BE27-4F077821B6BE

Q37947095-0B2A8827-6DFB-411B-817B-764800D7BDBA

Q37947095-0CA016F5-A760-4C66-B740-172FD04AD99E

Q37947095-0CD25D48-6157-485D-A56F-695C03A441F1

Q37947095-0EDFF2C3-642B-47DB-A012-05E3AA268259

P2888

Q37947095-E5ACC743-F4F4-4E48-8E71-EE1049AD20E4

P304

Q37947095-D3DC375A-1D21-4FDE-B313-A468A04A2DDE

P31

Q37947095-5AEA40E8-4E6A-4385-8F5F-ED7B97C5D9CE

P356

Q37947095-7D6E0F61-0F54-4405-801F-3B909CD924D8

P433

Q37947095-73CF87DD-9305-4B34-83C3-787B8492B8FE

P478

Q37947095-45E24637-C377-4BBD-A6AC-18CB539FF2AC

P577

Q37947095-C52C280F-C106-49A6-A7A6-F4663383345F

P5875

Q37947095-9D9AB6E9-1886-47E5-9051-E127A75C710E

P698

Q37947095-0FBE7892-0FCE-41BB-BA9F-AC06CA96275C

P921

Q37947095-40A1BEDE-3340-4574-A9E6-4E7B29EC2B8E

P356

NRENDO.2011.156

P1433

Nature Reviews Endocrinology

P1476

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

@en

P2093

Christoph U Correll

http://www.w3.org/2001/XMLSchema#string

Johan Detraux

http://www.w3.org/2001/XMLSchema#string

Marc De Hert

http://www.w3.org/2001/XMLSchema#string

Ruud van Winkel

http://www.w3.org/2001/XMLSchema#string

Weiping Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Management of antipsychotic-related weight gain

International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.

P2888

nrendo.2011.156

P304

114-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRENDO.2011.156

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51726975

http://www.w3.org/2001/XMLSchema#string

P698

22009159

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio